IS5100A - Meðferð á nýrnabólguhelluroða (lupus nephritis) með efnasamböndum sem eru mótefni gegn CD40L - Google Patents

Meðferð á nýrnabólguhelluroða (lupus nephritis) með efnasamböndum sem eru mótefni gegn CD40L

Info

Publication number
IS5100A
IS5100A IS5100A IS5100A IS5100A IS 5100 A IS5100 A IS 5100A IS 5100 A IS5100 A IS 5100A IS 5100 A IS5100 A IS 5100A IS 5100 A IS5100 A IS 5100A
Authority
IS
Iceland
Prior art keywords
treatment
lupus nephritis
cd40l antibodies
cd40l
antibodies
Prior art date
Application number
IS5100A
Other languages
English (en)
Inventor
L. Kalled Susan
W. Thomas David
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of IS5100A publication Critical patent/IS5100A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IS5100A 1997-01-10 1999-06-30 Meðferð á nýrnabólguhelluroða (lupus nephritis) með efnasamböndum sem eru mótefni gegn CD40L IS5100A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3467397P 1997-01-10 1997-01-10
PCT/US1997/023482 WO1998030240A1 (en) 1997-01-10 1997-12-31 Treatment of lupus nephritis with anti-cd40l compounds

Publications (1)

Publication Number Publication Date
IS5100A true IS5100A (is) 1999-06-30

Family

ID=21877889

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5100A IS5100A (is) 1997-01-10 1999-06-30 Meðferð á nýrnabólguhelluroða (lupus nephritis) með efnasamböndum sem eru mótefni gegn CD40L

Country Status (19)

Country Link
US (2) US20030031668A1 (is)
EP (2) EP0948355A1 (is)
JP (1) JP2001508441A (is)
KR (2) KR20000070034A (is)
CN (2) CN1247472A (is)
AU (1) AU5709798A (is)
BR (1) BR9714523A (is)
CA (1) CA2277222A1 (is)
CZ (1) CZ297680B6 (is)
EA (2) EA200501076A1 (is)
EE (1) EE9900273A (is)
HU (1) HUP0000833A3 (is)
IL (1) IL130784A0 (is)
IS (1) IS5100A (is)
NO (1) NO993274L (is)
NZ (1) NZ337072A (is)
PL (1) PL190663B1 (is)
TR (7) TR200001248T2 (is)
WO (1) WO1998030240A1 (is)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
HUP0101689A3 (en) * 1998-04-03 2004-08-30 Trustees Of Darmouth College H Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease
IL126681A0 (en) * 1998-10-21 1999-08-17 Opperbas Holding Bv Treatment of trauma-related conditions
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
CN104611339A (zh) 1998-12-14 2015-05-13 遗传研究所有限责任公司 细胞因子受体链
US6171795B1 (en) * 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
WO2001068133A1 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
AU8867501A (en) * 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
KR20040023565A (ko) * 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
HUE049161T2 (hu) 2003-12-23 2020-09-28 Genentech Inc Új anti-IL13 antitestek és alkalmazásaik
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
CN100369932C (zh) * 2005-04-07 2008-02-20 苏州大学 抗人cd154单克隆抗体及其应用
EP2367849B1 (en) * 2008-12-05 2017-11-01 ALS Therapy Development Institute Method for the treatment of neurodegenerative diseases
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
WO2012031122A2 (en) * 2010-09-03 2012-03-08 Immport Therapeutics, Inc. Methods and compositions for the diagnosis and treatment of cancer and autoimmune disorders
BR112016004437A2 (pt) 2013-09-13 2017-10-17 Genentech Inc métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
SG10201802525QA (en) 2013-09-13 2018-04-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
JP2017525370A (ja) 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
AU2016317768A1 (en) * 2015-08-31 2018-02-22 Merck Patent Gmbh Methods for the modulation of LGALS3BP to treat systemic lupus erythematosus
CN117843789A (zh) 2017-05-24 2024-04-09 Als治疗发展学会 治疗性抗cd40配体抗体
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
MX2023009100A (es) 2021-02-03 2023-09-25 Mozart Therapeutics Inc Agentes aglutinantes y métodos para usar los mismos.
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
JP2000503659A (ja) * 1996-01-16 2000-03-28 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティー オブ ニューヨーク 自己抗体の沈着以外の開始点を有する炎症性腎疾患を処置するためのｔ―ｂａｍ（ｃｄ４０―ｌ）技術の治療的適用
WO1997034473A1 (en) * 1996-03-21 1997-09-25 The Trustees Of Columbia University In The City Of New York Craf1 (traf-3) isoforms and uses thereof

Also Published As

Publication number Publication date
IL130784A0 (en) 2001-01-28
TR200001250T2 (tr) 2001-03-21
WO1998030240A1 (en) 1998-07-16
KR100618081B1 (ko) 2006-08-30
CZ297680B6 (cs) 2007-03-07
EA200501076A1 (ru) 2006-06-30
EP1357131A2 (en) 2003-10-29
EE9900273A (et) 2000-02-15
TR199902191T2 (xx) 1999-12-21
CN1572325A (zh) 2005-02-02
NO993274L (no) 1999-09-10
EP1357131A3 (en) 2004-02-11
CZ244499A3 (cs) 1999-10-13
TR200001248T2 (tr) 2000-07-21
EA006314B1 (ru) 2005-10-27
US20030031668A1 (en) 2003-02-13
TR200001251T2 (tr) 2000-09-21
KR20050089165A (ko) 2005-09-07
EA199900636A1 (ru) 2000-02-28
CN1247472A (zh) 2000-03-15
NO993274D0 (no) 1999-07-01
KR20000070034A (ko) 2000-11-25
PL190663B1 (pl) 2005-12-30
JP2001508441A (ja) 2001-06-26
TR200001249T2 (tr) 2000-11-21
NZ337072A (en) 2000-12-22
US20070190053A1 (en) 2007-08-16
TR200001247T2 (tr) 2002-06-21
AU5709798A (en) 1998-08-03
EP0948355A1 (en) 1999-10-13
HUP0000833A3 (en) 2001-09-28
CA2277222A1 (en) 1998-07-16
PL334495A1 (en) 2000-02-28
TR200001246T2 (tr) 2000-07-21
HUP0000833A2 (en) 2000-07-28
BR9714523A (pt) 2000-05-02

Similar Documents

Publication Publication Date Title
IS5100A (is) Meðferð á nýrnabólguhelluroða (lupus nephritis) með efnasamböndum sem eru mótefni gegn CD40L
PL339860A1 (en) Methods of modulating the action of serine/threonine protein kinase by means of compounds based on 5-azaquinoxaline
DE69840349D1 (de) Omatischem herunterladen
ZA99161B (en) Ó-ketoamide inhibitors of 20S proteasome.
ID24323A (id) Proses hidrosianasi yang tertingkatkan
DK1077940T3 (da) 4-Phenylpiperidiner til behandling af pruritiske dermatoser
DE19882742T1 (de) Hahnhalteteil
DE69840142D1 (de) Kathodenbogen-Beschichtungsgerät
DK0923978T3 (da) Fremgangsmåde til behandling af röggas
DK0930091T3 (da) Fremgangsmåde til behandling af röggasser
EP1212075A4 (en) PEPTIDES CAPABLE OF MODULATING THE FUNCTION OF MEMBERS OF THE CD66 FAMILY (CEACAM)
DE69839396D1 (de) Schaltung zur taktwiederherstellung
ID25893A (id) Proses pelletisasi
ATE216355T1 (de) Klärschlammvererdung
DE69835190D1 (de) Schaltung zur Taktrückgewinnung
DE69914157D1 (de) Entwicklerempfangvorrichtung
DK0928183T3 (da) Anvendelse af 1-hydroxy-2-pyridoner til behandling af seborrhoisk dermatitis
DK0862939T3 (da) Fremgangsmåde til behandling af röggas
DK1054868T3 (da) Substituerede pyridinoarylpiperaziner egnede til behandling af prostatahyperplasi
TW375295U (en) Holding device for the components of the computer
IL121903A0 (en) Control circuit for water distiller
AU7279994A (en) Water activated chemical current source
ID24181A (id) Proses kimia
IL124946A0 (en) Cooking aid of the coarse-grained type
NO972973L (no) Renseanlegg